DebraMcGarry

Dallas-based Cytoclonal (CYPH), which is developing the cancer gene inhibitors using the company’s Oasis technology, said it has produced the BCL cancer gene inhibitor involved in lymphoma, skin and small-cell lung cancer.

Oasis is a collection of inhibitors of various human genes, including BCL, c-RAF, and PKC-(alpha) associated with different types of cancers.

The Oasis “library” of inhibitors “could be instrumental in understanding human gene function and in making gene-based drugs," said Dr. Arthur Bollon, Cytoclonal’s chairman.

Cytoclonal said it’s expanding the Oasis library to include inhibitors to all human genes, focusing on those involved in human disease.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.